Table 1 Studies on clinical effectiveness of omalizumab in patients with severe asthma
Mediators and parameters | Biologic sample/procedure | Patients | Effects of omalizumab treatment | References |
|---|---|---|---|---|
ET-1 FeNO ECP Eosinophils count FEV1 | EBC EB Blood Blood Spirometry | 19 severe asthmatics 9/19 omalizumab (+) | ↓ ↓ ↓ ↓ ↑ | [32] |
RANTES/CCL5 FeNO ECP Eosinophils count | EBC EB Blood Blood | 19 severe asthmatics 9/19 omalizumab (+) | ↓ ↓ ↓ ↓ | [33] |
Eosinophils count | Blood | 13 severe sthmatics 13/13 omalizumab (+) | ↓ | [34] |
Quality of life PEF Unscheduled visits Exacerbations FeNO CalvNO Eosinophils count Airway-wall thickness | Questionnaire Spirometry Clinical data Clinical data EB EB Sputum CT | 26 severe asthmatics 26/26 omalizumab (+) | ↑ ↑ ↓ ↓ ↓ ↓ ↓ ↓ | [35] |
Exacerbations Systemic steroids ACT score | Clinical data Clinical data Questionnaire | 22 severe asthmatics 22/22 omalizumab (+) | ↓ ↓ ↑ | [36] |
Airway-wall thickness Eosinophils count | Bronchial biopsies | 11 severe asthmatics 11/11 omalizumab (+) | ↓ ↓ | [31] |
Bronchial smooth muscle proteins | Bronchial biopsies | 8 severe astmatics 8/8 omalizumab (+) | ↓ | [37] |